|
Oct 11
|
High Growth Tech Stocks In Hong Kong October 2024
|
|
Oct 10
|
High Growth Tech Stocks in Hong Kong for October 2024
|
|
Oct 10
|
Top High Growth Tech Stocks In Hong Kong October 2024
|
|
Oct 9
|
High Growth Tech Stocks In Hong Kong This October 2024
|
|
Oct 8
|
Exploring 3 High Growth Tech Stocks in Hong Kong
|
|
Oct 8
|
Innovent and ASK Pharm to commercialise limertinib for lung cancer
|
|
Oct 8
|
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
|
|
Jul 26
|
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
|
|
Jun 19
|
Innovent Reports Oncology Pipeline Updates at Investor Meeting
|
|
Jun 17
|
Exploring Hidden Gems on SEHK: 3 Stocks Estimated as Undervalued in June 2024
|
|
Jun 14
|
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
|
|
Apr 16
|
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
|
|
Mar 27
|
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
|
|
Jan 9
|
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
|
|
Dec 19
|
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
|
|
Dec 18
|
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
|
|
Dec 7
|
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
|
|
Dec 6
|
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
|
|
Dec 1
|
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
|
|
Nov 30
|
Innovent's MSCI ESG Rating Upgraded to A
|